Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
110
Recruiting, any sponsor type, condition "schizophrenia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting110
- Completed1,442
110 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT05303064 · 220 participants (planned) · Start Jun 30, 2022 · Primary completion Dec 2027
Drug: OLZ/SAM; Olanzapine · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Encino, California · 47 sites in all
- MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial DysfunctionPivotal-lookingRecruiting
Mclean HospitalAcademic, hospital or other
NCT06191965 · 100 participants (planned) · Start Jun 1, 2024 · Primary completion Jan 31, 2027
Drug: MitoQ; Placebo · For: Schizophrenia and Related Disorders; Mitochondrial Alteration; Cognitive Impairment
Sites: New Haven, Connecticut; Belmont, Massachusetts; Lausanne, Switzerland
- Genetic Basis of the Risk and Consequences of Cannabis Exposure in HumansPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT06058702 · 215 participants (planned) · Start Sep 16, 2024 · Primary completion Dec 31, 2028
Drug: Delta-9-THC Very Low Dose; Placebo and 1 more · For: Schizophrenia; Cannabis Use Disorder
Sites: West Haven, Connecticut
- Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsPivotal-lookingRecruiting
Minerva NeurosciencesIndustry
NCT07565428 · 380 participants (planned) · Start Apr 23, 2026 · Primary completion Dec 2027
Drug: Roluperidone; risperidone and 3 more · For: Negative Symptoms of Schizophrenia
Sites: Bellflower, California; Culver City, California; Garden Grove, California · 13 sites in all
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPivotal-lookingRecruiting
MapLight TherapeuticsIndustry
NCT06887192 · 300 participants (planned) · Start Aug 15, 2025 · Primary completion Dec 2027
Drug: ML-007C-MA; Placebo · For: Psychosis Associated With Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 69 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07288567 · 166 participants (planned) · Start Jan 29, 2026 · Primary completion Dec 18, 2029
Drug: KarXT · For: Schizophrenia
Sites: Anaheim, California; Chino, California; Culver City, California · 36 sites in all
- Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaPivotal-lookingRecruiting
Newron Pharmaceuticals SPAIndustry
NCT07184619 · 400 participants (planned) · Start Jan 23, 2026 · Primary completion Mar 31, 2027
Drug: Evenamide 15 mg bid; Placebo · For: Treatment-resistant Schizophrenia
Sites: Los Angeles, California; Miami, Florida; Atlanta, Georgia · 25 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07221877 · 60 participants (planned) · Start Jan 20, 2026 · Primary completion Dec 30, 2027
Drug: Xanomeline/trospium chloride · For: Schizophrenia
Sites: Little Rock, Arkansas; Bellflower, California; Chino, California · 16 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07908680 · 36 participants (planned) · Start Nov 4, 2026 · Primary completion Mar 6, 2028
Drug: XEP527; Placebo · For: Schizophrenia
Sites: Bentonville, Arkansas
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07424404 · 400 participants (planned) · Start Apr 7, 2026 · Primary completion Mar 8, 2030
Drug: KarXT; KarX-EC · For: Schizophrenia; Autism-Related Irritability
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 105 sites in all
- Sequential Treatment Approaches for Treatment-Resistant SchizophreniaPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT07918222 · 300 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 1, 2030
Drug: [Phase 1] Clozapine; [Phase 1] Aripiprazole and 1 more · For: Treatment-resistant Schizophrenia
Sites: Shanghai, China
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07615426 · 64 participants (planned) · Start Mar 2, 2026 · Primary completion Jun 21, 2027
Drug: Aticaprant; Placebo · For: Schizophrenia
Sites: Garden Grove, California; Atlanta, Georgia; Chicago, Illinois · 8 sites in all
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06229210 · 300 participants (planned) · Start Jan 25, 2024 · Primary completion Apr 28, 2032
Drug: Lumateperone · For: Schizophrenia; Bipolar Disorder; Autism Spectrum Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 65 sites in all
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06540833 · 370 participants (planned) · Start Aug 15, 2024 · Primary completion Sep 30, 2028
Drug: ITI-1284; Placebo · For: Psychotic Disorders; Alzheimer Disease
Sites: Anaheim, California; Los Alamitos, California; Newport Beach, California · 71 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06882785 · 250 participants (planned) · Start Jun 10, 2025 · Primary completion Sep 23, 2028
Drug: KarXT · For: Schizophrenia
Sites: Kōnan, Japan; Nagoya, Japan; Toyoake, Japan · 56 sites in all
- Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)Recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07379827 · 1,500 participants (planned) · Start Feb 26, 2026 · Primary completion Jun 20, 2028
Drug: Xanomeline and trospium chloride (KarXT) · For: Schizophrenia
Sites: Bryant, Arkansas; Anaheim, California; Chino, California · 68 sites in all
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruiting
TG Therapeutics, Inc.Industry
NCT07680946 · 60 participants (planned) · Start Jul 27, 2026 · Primary completion Dec 12, 2028
Drug: Ublituximab · For: Schizophrenia
Sites: Little Rock, Arkansas; Richardson, Texas
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07686263 · 472 participants (planned) · Start Aug 20, 2026 · Primary completion Mar 3, 2029
Drug: Xanomeline/Trospium Chloride; Placebo · For: Schizophrenia
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 54 sites in all
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Pivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT06585787 · 406 participants (planned) · Start Sep 26, 2024 · Primary completion Nov 24, 2026
Drug: KarXT; Placebo · For: Alzheimer Disease
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 296 sites in all
Université de SherbrookeAcademic, hospital or other
NCT06651112 · 18 participants (planned) · Start Nov 1, 2024 · Primary completion Dec 1, 2027
Drug: Antipsychotic drugs · For: First Episose Psychosis; Metabolic Disease; Psychosis; Episode
Sites: Sherbrooke, Canada
China Medical University HospitalAcademic, hospital or other
NCT06021197 · 90 participants (planned) · Start Oct 12, 2023 · Primary completion Dec 2027
Drug: NMDAE; Placebo Cap · For: Schizophrenia
Sites: Taichung, Taiwan
China Medical University HospitalAcademic, hospital or other
NCT04917302 · 60 participants (planned) · Start Oct 13, 2020 · Primary completion Nov 2026
Drug: NMDAE plus AIFA; NMDAE plus Placebo Cap · For: Schizophrenia
Sites: Taichung, Taiwan
China Medical University HospitalAcademic, hospital or other
NCT04959201 · 90 participants (planned) · Start Nov 30, 2020 · Primary completion Dec 2026
Drug: NMDAE plus AO; NMDAE plus Placebo Cap · For: Schizophrenia
Sites: Taichung, Taiwan
MapLight TherapeuticsIndustry
NCT07459647 · 500 participants (planned) · Start Mar 31, 2026 · Primary completion Feb 2030
Drug: ML-007C-MA · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Bellflower, California · 45 sites in all
Bosnalijek D.DIndustry
NCT07858565 · 500 participants (planned) · Start Oct 30, 2025 · Primary completion Apr 2027
Drug: Quetiapine (drug); quetiapine + aripiprazole and 1 more · For: Schizophrenia; Bipolar Affective Disorder
Sites: Sarajevo, Bosnia and Herzegovina
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.